ArticleJournal of cachexia, sarcopenia and muscle2025
Fibroblast Growth Factor 23 and Sarcopenia in Maintenance Haemodialysis Population.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of Impaired Skeletal Muscle Regeneration and Therapeutic Approaches in Aging and Chronic Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSarcopenia is defined as the loss of muscle mass, strength, and/or performance. It is strongly associated with all-cause mortality. Fibroblast growth factor 23 (FGF23) is markedly elevated in patients with chronic kidney disease, especially those receiving maintenance dialysis. FGF23 has previously been shown to have a direct role in cardiac dysfunction mediated through left ventricular hypertrophy. However, its role in the development of (or protection from) sarcopenia is uncertain. This study is aimed at determining the relationship between FGF23 and muscle-related parameters and to assess the effect of FGF23 on skeletal muscle myoblasts.
methodsA single centre, cross-sectional study examining maintenance haemodialysis patients was conducted. Sarcopenia was defined in accordance with the revised European Working Group on Sarcopenia in Older People and the Asian Working Group for Sarcopenia criteria. Clinical assessment methods included bioelectrical impedance analysis, anthropometric measurement, handgrip strength and physical performance appraisal. Both intact FGF23, which is biologically active, and the inactive C-terminal FGF23 were measured using enzyme-linked immunosorbent assays. The direct effects of FGF23 on skeletal muscle myoblast proliferation and myogenic differentiation were assessed using an in vitro culture system. Linear and logistic regression analyses were performed to examine the associations between FGF23 and muscle-related parameters and sarcopenia, respectively.
resultsEighty-one patients were included with a median age of 75 years (interquartile range 67-80), and 63% were male. Log-transformed serum FGF23 correlated positively with handgrip strength (r = 0.27, p = 0.01, 95% confidence interval (CI) 0.06-0.46) and calf circumference (r = 0.27, p = 0.01, 95% CI 0.06-0.46), and in multiple regression analyses, it was found to be a significant independent predictor of both handgrip strength (beta = 5.39, 95% CI 2.07-8.72) and sarcopenia (odds ratio = 0.14, 95% CI 0.02-0.75). FGF23 was found to promote myoblast proliferation but attenuate myogenic differentiation. At 48 h of differentiation, the expressions of MyoG and MyoD were significantly lower in cells treated with FGF23 than the control. The fusion index and myotube diameters were reduced on Day 7 of differentiation in FGF23-treated cells compared to the control.
conclusionsHigher serum FGF23 levels were associated with stronger handgrip strength and lower odds of having sarcopenia in maintenance haemodialysis patients. Our findings suggest that supraphysiological levels of FGF23 might play a role in muscle regeneration by promoting myoblast proliferation but repressing myogenic differentiation to support the expansion of the proliferative pool. FGF23 could potentially serve as a serum biomarker for muscle health in dialysis populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.